### PATENT COOPERATION TREATY

### **PCT**

REC'D	0	1	JUL	2005
WIPO				PCT

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	T —						
4-33239A/HO 81	FOR FURTHER A	CTION	See Form PCT/IPEA/416				
International application No. PCT/EP2004/006795	International filing date 23.06.2004		Priority date (day/month/year) 24.06.2003				
International Patent Classification (IPC) or CO7D211/46, C07D207/08, C07D2	national classification and II 11/22, C07D409/14, A	PC 61K31/40, A61K31/40	25, A61K31/452, A61P11/00				
Applicant NOVARTIS AG et al.							
	<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>						
2. This REPORT consists of a total	of 7 sheets, including the	nis cover sheet.					
<ol><li>This report is also accompanied I</li></ol>	by ANNEXES, comprisir	ng:					
a. 🛘 sent to the applicant and t	o the International Bure	au) a total of sheets, as	s follows:				
sheets of the descript and/or sheets contain Administrative Instruc	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.							
b. (sent to the International E sequence listing and/or tal Box Relating to Sequence							
4. This report contains indications re	lating to the following it						
		3111 <b>5.</b>					
— — — — — — — — — — — — — — — — — — —	nion	•	·				
= 1 Honey	- Control in Profits						
₩ - · · ·	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
☑ Box No. V Reasoned state	Lack of unity of invention						
Box No. VI Certain docume	ents cited	oupporting such stateme	ent ·				
Box No. VII Certain defects in the International application							
☐ Box No. VIII Certain observations on the international application							
Date of submission of the demand		Date of completion of this	report				
01.04.2005		30.06.2005					
Name and mailing address of the internation preliminary examining authority:	al	Authorized Officer	_				
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 5236	56 enmu d	Telephone No. +49 89 239	60- 33Ed Summing				
Fax: +49 89 2399 - 4465	so epiniu u	Kollmannsbegg	3C1 17.				

International application No. PCT/EP2004/006795

	Bo	x No. I Basis of the report						
_								
1.	<ol> <li>With regard to the language, this report is based on the international application in the language in which it filed, unless otherwise indicated under this item.</li> </ol>							
		which is the language of a translation furnished for the purposes of:						
		☐ international search (under Rules 12.3 and 23.1(b)) ☐ publication of the international application (under Rule 12.4) ☐ international preliminary examination (under Rules 55.2 and/or 55.3)						
2. With regard to the elements* of the international application, this report is based on (replacement sheets have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in report as "originally filed" and are not annexed to this report):								
	Des	scription, Pages						
	1-39	as originally filed						
	Clai	ms, Numbers						
	1-17	as originally filed						
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing						
3.		The amendments have resulted in the cancellation of:  ☐ the description, pages ☐ the claims, Nos. ☐ the drawings, sheets/figs						
		☐ the sequence listing (specify): ☐ any table(s) related to sequence listing (specify):						
4.	□ had Sup	This report has been established as if (some of) the amendments annexed to this report and listed below not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the						
		☐ the description, pages ☐ the claims, Nos. ☐ the drawings, sheets/figs ☐ the sequence listing (specify):						
		any table(s) related to sequence listing (specify):						
	*	If item 4 applies, some or all of these sheets may be marked "superseded."						

International application No. PCT/EP2004/006795

	ox No. III Non-establishmen oplicability	t of o	pinion with regard to novelty, inventive step and industrial	_	
1. Ti	<ol> <li>The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- obvious), or to be industrially applicable have not been examined in respect of:</li> </ol>				
	ostalimiod in respect of.				
$\boxtimes$					
	because:				
	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):				
	(op-on.)/.				
	• • • • • • • • • • • • • • • • • • • •				
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
	the written form		has not been furnished		
			does not comply with the standard		
	the computer readable form		has not been furnished	!	
			does not comply with the standard		
the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form on comply with the technical requirements provided for in Annex C-bis of the Administrative Instruction			and the		
	See separate sheet for further details				

International application No. PCT/EP2004/006795

-	Во	x No. IV Lack of unity of i	nventi					
1	Box No. IV Lack of unity of invention  In response to the invitation to restrict or pay additional fees, the applicant has:  restricted the claims.  paid additional fees.							
	□ paid additional fees under protest. □ neither restricted nor paid additional fees.							
		This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.						
3.	. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3							
		complied with.						
		not complied with for the foll	owing ı	easons:				
	see separate sheet							
4.	Cor	nsequently, this report has be	en esta	ıblished in re	spect of the following	parts of the international application:		
		all parts.				parto of the international application:		
	$\boxtimes$	★ The parts relating to claims Nos. 1-17 (in part).						
				. ,				
_	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
1.		ement						
	Nov	elty (N)	Yes: No:	Claims Claims	7-9,17 1-6,10-16	;		
	Inve	ntive step (IS)	Yes: No:	Claims Claims	1-17			
	Indu	strial applicability (IA)	Yes: No:	Claims Claims	1-17			
2.	Citat	ions and explanations (Rule 7	70.7):					

see separate sheet

International application No. PCT/EP2004/006795

#### Box No. VI Certain documents cited

 Certain published documents (Rule 70.10) and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

#### Re Item V

#### V-1. State of the art:

The documents cited in the search report are numbered in consecutive order.

#### V-2. Novelty (Art. 33(2) PCT)

All the documents D2-D13 disclose compounds (see passages indicated in the search report) which are included in the scope of at least independent claim 1 and are described to have spasmolytic activity or are explicitly disclosed as muscarinic M3 receptor ligands. At least the independent claims 1, 10-16 are thus not novel. Claims 7-9 are novel since the claimed example compounds are not disclosed individually. Claim 17 is novel since the cited documents do not disclose compounds which have an alkylamino substituent attached to the quaternised N-atom of the ring.

### V-3. Inventive step (Art. 33(3) PCT)

D2-D13 disclose compounds disclosed as having spasmolytic activity and/or being muscarinic receptor ligands. Since the disclosed compounds are included in the claimed scope or have been excluded only by proviso-like definitions (the split-up definitions L/M and R5 in claim 1), the problem of finding further muscarinic receptor ligands has been solved in an obvious way. It is presently not apparent that the dependent claims contain structural features which are not obviously derivable from D2-D13. The intermediates of claim 17 would fulfil Art. 33(3) PCT only if they were intermediates in the production of with inventive end products

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/006795

## Re Item VI Certain documents cited

Certain published documents

Application No Patent No Publication date (day/month/year)

Filing date (day/month/year)

Priority date (valid claim) (day/month/year)

WO-A-03/087094

23-10-2003

11-04-2003

11-04-2003